Stemline And Karyopharm Want More Time At EMA
The CHMP Stiil Has Issues Over Filings For Tagraxofusp And Selinexor
A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.
